Advances in ophthalmic therapeutic delivery: A comprehensive overview of present and future directions

被引:5
作者
Torkashvand, Ali [1 ]
Izadian, Afshin [2 ]
Hajrasouliha, Amir [1 ]
机构
[1] Indiana Univ Sch Med, Dept Ophthalmol, 1160 West Michigan St, Indianapolis, IN 46202 USA
[2] Purdue Univ, Elect & Comp Engn Technol, W Lafayette, IN USA
关键词
Ophthalmic drug delivery; Implants; Nanoparticles; Gene delivery; Gene therapy; Sustained release; Suprachoroidal delivery; Encapsulated cell therapy; Microneedle; Hydrogel; Port delivery system; Electrophoresis; Transscleral delivery; Retinal disease; FLUOCINOLONE ACETONIDE IMPLANT; CILIARY NEUROTROPHIC FACTOR; DIABETIC MACULAR EDEMA; DEXAMETHASONE INTRAVITREAL IMPLANT; MESOPOROUS SILICA NANOPARTICLES; ANTERIOR-CHAMBER MIGRATION; CELL INTRAOCULAR IMPLANTS; OCULAR DRUG-DELIVERY; DRY EYE DISEASE; SUSTAINED-RELEASE;
D O I
10.1016/j.survophthal.2024.07.002
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Ophthalmic treatment demands precision and consistency in delivering therapeutic agents over extended periods to address many conditions, from common eye disorders to complex diseases. This diversity necessitates a range of delivery strategies, each tailored to specific needs. We delve into various delivery cargos that are pivotal in ophthalmic care. These cargos encompass biodegradable implants that gradually release medication, nonbiodegradable implants for sustained drug delivery, refillable tools allowing flexibility in treatment, hydrogels capable of retaining substances while maintaining ocular comfort, and advanced nanotechnology devices that precisely target eye tissues. Within each cargo category, we explore cutting-edge research-level approaches and FDA-approved methods, providing a thorough overview of the current state of ophthalmic drug delivery. In particular, our focus on nanotechnology reveals the promising potential for gene delivery, cell therapy administration, and the implantation of active devices directly into the retina. These advancements hold the key to more effective, personalized, and minimally- invasive ophthalmic treatments, revolutionizing the field of eye care.
引用
收藏
页码:967 / 983
页数:17
相关论文
共 202 条
  • [1] Abbey AM, 2023, INVEST OPHTH VIS SCI, V64
  • [2] Intravitreal Therapy for Uveitic Macular Edema-Ranibizumab versus Methotrexate versus the Dexamethasone Implant
    Acharya, Nisha R.
    Vitale, Albert T.
    Sugar, Elizabeth A.
    Holbrook, Janet T.
    Burke, Alyce E.
    Thorne, Jennifer E.
    Altaweel, Michael M.
    Kempen, John H.
    Jabs, Douglas A.
    [J]. OPHTHALMOLOGY, 2023, 130 (09) : 914 - 923
  • [3] Nanoparticle-based technologies for retinal gene therapy
    Adijanto, Jeffrey
    Naash, Muna I.
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2015, 95 : 353 - 367
  • [4] Adverum Biotechnologies Inc, 2023, Report No.: NCT05536973
  • [5] LIPOSOME-BOUND CYCLOSPORINE - RETINAL TOXICITY AFTER INTRAVITREAL INJECTION
    ALGHADYAN, AA
    PEYMAN, GA
    KHOOBEHI, B
    LIU, KR
    [J]. INTERNATIONAL OPHTHALMOLOGY, 1988, 12 (02) : 105 - 107
  • [6] Gene transfer into the mouse retina mediated by an adeno-associated viral vector
    Ali, RR
    Reichel, MB
    Thrasher, AJ
    Levinsky, RJ
    Kinnon, C
    Kanuga, N
    Hunt, DM
    Bhattacharya, SS
    [J]. HUMAN MOLECULAR GENETICS, 1996, 5 (05) : 591 - 594
  • [7] Considerations for Polymers Used in Ocular Drug Delivery
    Allyn, Megan M.
    Luo, Richard H.
    Hellwarth, Elle B.
    Swindle-Reilly, Katelyn E.
    [J]. FRONTIERS IN MEDICINE, 2022, 8
  • [8] Organic Nanocarriers for Bevacizumab Delivery: An Overview of Development, Characterization and Applications
    Alves, Aline de Cristo Soares
    Bruinsmann, Franciele Aline
    Guterres, Silvia Staniscuaski
    Pohlmann, Adriana Raffin
    [J]. MOLECULES, 2021, 26 (14):
  • [9] Alzaabi Manal, 2020, Am J Ophthalmol Case Rep, V20, P100922, DOI 10.1016/j.ajoc.2020.100922
  • [10] [Anonymous], Study Record